OrbiMed’s Agile Therapeutics AGRX Stock Holding History

OrbiMed’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-600	Closed	-$2.23M	–	163
2020 Q1	$2.23M	Buy	+600	New	+$3.44M	0.04%	126

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DCM

DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

OrbiMed's AGRX Position: Q2 2020 in Review

OrbiMed sold out of Agile Therapeutics (AGRX) in Q2 2020, closing a stake of 600 shares — an estimated $2.23M sold.

OrbiMed first reported a position in AGRX in Q1 2020 and held it in 1 quarter. The position peaked at $2.23M in Q1 2020. 79 funds tracked by Wall St. Rank hold AGRX as of Q2 2020.

OrbiMed reported no remaining Agile Therapeutics position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 600 Agile Therapeutics shares in Q2 2020, an estimated $2.23M.
OrbiMed first reported a position in Agile Therapeutics in Q1 2020 and held it in 1 quarter.
OrbiMed's Agile Therapeutics position peaked at $2.23M in Q1 2020.
79 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.